论文部分内容阅读
目的探讨拉米夫定联合阿德福韦对乙型肝炎患者免疫应答与浆细胞样树突状细胞功能变化的影响。方法收集48例慢性乙型肝炎患者,随机分为对照组和实验组,每组各24例,在常规治疗基础上,对照组患者给予拉米夫定治疗,实验组在对照组基础上给予阿德福韦治疗,治疗结束后,对所有患者的血清AST、ALT、IFN-α水平及外周血CD4+、CD8+T细胞、CD4+/CD8+、p DCs水平进行检测。结果治疗后,与对照组比较,实验组患者的外周血CD4+T细胞及CD4+/CD8+水平较高(P<0.05);实验组患者的血清IFN-α及外周血p DCs水平较高(P<0.05);实验组患者的血清AST、ALT水平较低(P<0.05)。结论拉米夫定联合阿德福韦能够显著提高乙型肝炎患者的免疫应答以及浆细胞样树突状细胞功能,改善肝功能。
Objective To investigate the effects of lamivudine combined with adefovir on the immune response of hepatitis B patients and the changes of plasmacytoid dendritic cells. Methods 48 cases of chronic hepatitis B were collected and randomly divided into control group and experimental group, 24 cases in each group. On the basis of routine treatment, patients in control group were treated with lamivudine. The experimental group was given A After treatment, the levels of AST, ALT, IFN-α, CD4 +, CD8 + T cells, CD4 + / CD8 + and p DCs in peripheral blood were measured in all patients after treatment. Results Compared with the control group, the levels of CD4 + T cells and CD4 + / CD8 + in the peripheral blood of the experimental group were significantly higher (P <0.05), and the levels of IFN-α and p DCs in the experimental group were higher (P <0.05). The levels of serum AST and ALT in the experimental group were lower (P <0.05). Conclusion lamivudine combined with adefovir can significantly improve the immune response in patients with hepatitis B and plasma-like dendritic cell function, improve liver function.